Skip to main content
. 2020 Jul 9;13:1756284820936536. doi: 10.1177/1756284820936536

Figure 3.

Figure 3.

Treatment failure among patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with vedolizumab at post-induction, week 30 and week 52.

CMV, cytomegalovirus.